Completed PHASE3 INTERVENTIONAL 1-arm NCT01512966

Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema) (VIVID-Japan)

An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema

Sponsor: Bayer

Conditions Macular Edema

Interventions VEGF Trap-Eye (BAY86-5321)

Updated 7 times since 2017 Last updated: Oct 8, 2014 Started: Jan 31, 2012 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Macular Edema and is currently completed. Bayer leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Regeneron Pharmaceuticals

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Kagoshima, Japan , Kashihara, Japan , Kawasaki, Japan , Kita, Japan , Kobe, Japan , Kyoto, Japan , Maebashi, Japan , Matsuyama, Japan , Mito, Japan , Okayama, Japan and 7 more locations